Full Text View
Tabular View
Study Results
Related Studies
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
This study has been completed.
Study NCT00119262   Information provided by National Cancer Institute (NCI)

First Received on July 12, 2005.   Last Updated on February 26, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
bevacizumab
filgrastim
pegfilgrastim
cyclophosphamide
doxorubicin hydrochloride
paclitaxel
Additional drug interventions recognized in this trial
Doxorubicin
Lenograstim
More general drug interventions related to this trial
Adjuvants, Immunologic
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
National Cancer Institute (NCI)
North Central Cancer Treatment Group
Cancer and Leukemia Group B


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services